Neuphoria Therapeutics In... (NEUP)
NASDAQ: NEUP
· Real-Time Price · USD
6.84
-0.31 (-4.34%)
At close: Jun 06, 2025, 3:45 PM
6.82
-0.37%
After-hours: Jun 06, 2025, 05:51 PM EDT
Company Description
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders.
The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Neuphoria Therapeutics Inc.
| Country | United States |
| IPO Date | Dec 16, 2021 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Spyridon Papapetropoulos M.D., Ph.D. |
Contact Details
Address: 100 Summit Dr Burlington, United States | |
| Website | http://www.neuphoriatx.com |
Stock Details
| Ticker Symbol | NEUP |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US64136E1029 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Executive Officer, President & Director |
| Adrian Hinton BEC, F.C.A. | Financial Controller |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer |
| Elizabeth Doolin | Senior Vice President of Clinical Development |
| Rajeev Chandra B.Com., C.A., M.B.A. | Company Secretary |